CancerUnfiltered.com, an online magazine created to focus on patient voices, has featured an article written by our LSN team on the Brigimadlin Petition in this month’s issue, highlighting the critical need to keep the BRIGHTLINE trial for brigimadlin alive. This drug is hope for those with few treatment options.
For patients with DDLPS, a rare, aggressive soft tissue sarcoma, brigimadlin represented hope for a future. In early trials, tumors shrank. Disease was controlled. Lives were extended. For some, it offered the gift of time, the rarest and most precious thing cancer steals; time to celebrate milestones, to be present with their children, to live without counting down the days.
Soon after announcing the trial failed to meet primary endpoints, Boehringer Ingelheim (BI), the company developing brigimadlin, halted the trial. Only BRIGHTLINE trial participants currently enrolled are able to continue brigimadlin. No new patients will have access to brigimadlin. We believe that there is more research to be done based on the fact that brigimadlin did help some patients remain stable.
Sign & share the petition here: https://www.brigimadlinpetition.org/
READ FULL ARTICLE HERE
